Holen Sie sich die Stockscreener-App
25.35
0.06%
0.0156
Xoma Corporation Aktie (XOMAO) Neueste Nachrichten
Xoma Royalty Faces Dual Crisis: Clinical Trial Failure and Legal Probe - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - yourwyominglink.com
Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
Aug Reactions: Can XOMA Royalty Corporation deliver alphaTrade Performance Summary & Community Trade Idea Sharing - baoquankhu1.vn
Technical Reactions to XOMAP Trends in Macro Strategies - Stock Traders Daily
XOMA royalty announces CFO transition - MSN
XOMA Royalty Appoints New Chief Financial Officer - TipRanks
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
(XOMAO) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Discipline and Rules-Based Execution in XOMA Response - Stock Traders Daily
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed By Investing.com - Investing.com Nigeria
XOMA Royalty Appoints New CFO; Shares Fall - marketscreener.com
Xoma announces CFO Burns to step down, Trigilio to succeed - TipRanks
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
XOMA Highlights Royalty Growth Strategy in Updated Presentation - TipRanks
Xoma Royalty announces CFO transition - marketscreener.com
XOMA Royalty Announces CFO Transition - marketscreener.com
Institutional investors are XOMA Royalty Corporation's (NASDAQ:XOMA) biggest bettors and were rewarded after last week's US$40m market cap gain - simplywall.st
What is the fair value estimate for XOMA Royalty Corporation (X0M1) stock in 2025CEO Change & Fast Exit Strategy with Risk Control - ulpravda.ru
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - ulpravda.ru
How XOMA Royalty Corporation(X0M) stock trades under stagflationJuly 2025 Spike Watch & Smart Allocation Stock Reports - ulpravda.ru
Trading the Move, Not the Narrative: (XOMAP) Edition - Stock Traders Daily
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty ... - Bluefield Daily Telegraph
H.C. Wainwright Maintains XOMA Corp(XOMA.US) With Buy Rating, Maintains Target Price $97 - 富途牛牛
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
Implied Volatility Surging for XOMA Royalty Stock Options - sharewise.com
Can Pressure Sensitive Systems India Limited Achieve Earnings Growth in a SlowdownStock Market Trends & Big Profit Low Investment - earlytimes.in
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Turnstone Biologics to be acquired by XOMA Royalty - MSN
Behavioral Patterns of XOMA and Institutional Flows - Stock Traders Daily
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement - MSN
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners Maintains XOMA Corp(XOMA.US) With Buy Rating - 富途牛牛
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA By Investing.com - Investing.com Nigeria
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab - The Globe and Mail
Xoma Royalty and Takeda execute strategic royalty sharing transaction and amend existing agreement for mezagitamab - MarketScreener
2.92%
2.36%
Kapitalisierung:
|
Volumen (24h):